Micron Solutions (MICRD) 10-K 10 Mar 16 2015 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2015	Mar. 10, 2016	Jun. 30, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/
Entity Central Index Key	819,689
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Document Type	10-K
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Common Stock, Shares Outstanding		2,816,639
Entity Public Float			$ 17,471,600
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 272,291	$ 209,398
Trade accounts receivable, net of allowance for doubtful accounts of $60,000 at December 31, 2015 and $45,000 at December 31, 2014	2,798,353	3,536,747
Inventories	2,118,712	2,514,241
Prepaid expenses and other current assets	614,129	519,582
Total current assets	5,803,485	6,779,968
Assets held for sale, net	665,000	0
Property, plant and equipment, net	6,626,069	7,618,901
Intangible assets, net	18,645	134,022
Other assets	268,835	570,357
Total assets	13,382,034	15,103,248
Current liabilities:
Revolving line of credit, current portion	0	2,071,495
Equipment line of credit, current portion	35,718	0
Term notes payable, current portion	589,635	490,341
Subordinated promissory notes	473,135	0
Accounts payable	1,553,388	1,857,156
Accrued expenses and other current liabilities	275,777	405,975
Customer deposits	93,407	98,110
Deferred revenue, current	272,837	228,363
Liabilities from discontinued operations, current	0	320,056
Total current liabilities	3,293,897	5,471,496
Long-term liabilities:
Revolving line of credit, non-current portion	1,511,495	0
Equipment line of credit, non-current portion	301,132	0
Term notes payable, non-current portion	1,120,652	1,330,755
Subordinated promissory notes	0	445,452
Deferred revenue, non-current	272,181	610,430
Total long-term liabilities	3,205,460	2,386,637
Total liabilities	$ 6,499,357	$ 7,858,133
Commitments and Contingencies
Shareholders' equity:
Preferred stock, $0.001 par value; 2,000,000 shares authorized, none issued	$ 0	$ 0
Common stock, $0.01 par value; 10,000,000 shares authorized; 3,926,491 issued, 2,801,639 outstanding at December 31, 2015 and 3,926,491 issued, 2,778,339 outstanding at December 31, 2014	39,265	39,265
Additional paid-in-capital	11,381,536	11,336,693
Treasury stock at cost, 1,124,852 shares at December 31, 2015 and 1,148,152 shares at December 31, 2014	(3,069,496)	(3,133,883)
Accumulated other comprehensive income	0	42,502
Accumulated deficit	(1,468,628)	(1,039,462)
Total shareholders’ equity	6,882,677	7,245,115
Total liabilities and shareholders’ equity	$ 13,382,034	$ 15,103,248

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Consolidated Balance Sheets [Abstract]
Allowance for doubtful accounts receivable, current	$ 60,000	$ 45,000
Preferred stock, par value per share	$ 0.001	$ 0.001
Preferred stock, shares authorized	2,000,000	2,000,000
Preferred stock, shares issued	0	0
Common stock, par value per share	$ 0.01	$ 0.01
Common stock, shares authorized	10,000,000	10,000,000
Common stock, shares issued	3,926,491	3,926,491
Common stock, shares outstanding	2,801,639	2,778,339
Treasury stock, shares	1,124,852	1,148,152

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Consolidated Statements of Operations and Comprehensive Income (Loss) [Abstract]
Net sales	$ 21,495,184	$ 24,070,292
Cost of sales	18,332,346	19,432,241
Gross profit	3,162,838	4,638,051
Selling and marketing	1,086,586	1,015,279
General and administrative	2,355,484	2,322,795
Research and development	241,100	408,867
Total operating expenses	3,683,170	3,746,941
Income (loss) from continuing operations	(520,332)	891,110
Other income (expense):
Interest expense	(260,300)	(274,138)
Other income (expense), net	(10,212)	46,184
Total other expense, net	(270,512)	(227,954)
Income (loss) from continuing operations before income taxes	(790,844)	663,156
Income tax provision	932	2,168
Net income (loss) from continuing operations	(791,776)	660,988
Discontinued Operations:
Income (loss) from discontinued operations, net of tax provision of $0 for the years ended December 31, 2015 and 2014 (includes $42,502 accumulated other comprehensive income reclassification in 2015)	362,610	(1,779)
Net income (loss)	(429,166)	659,209
Other comprehensive income:
Reclassification of gains from foreign currency translation	(42,502)
Comprehensive income (loss)	$ (471,668)	$ 659,209
Earnings (loss) per share - basic
Continuing operations	$ (0.28)	$ 0.24
Discontinued operations	0.13	0
Earnings (loss) per share - basic	(0.15)	0.24
Earnings (loss) per share - diluted
Continuing operations	(0.28)	0.23
Discontinued operations	0.13	0
Earnings (loss) per share - diluted	$ (0.15)	$ 0.23
Weighted average common shares outstanding - basic	2,784,757	2,742,080
Weighted average common shares outstanding - diluted	2,784,757	2,863,098

Consolidated Statements of Ope5

Consolidated Statements of Operations and Comprehensive Income (Loss) (Parenthetical) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Consolidated Statements of Operations and Comprehensive Income (Loss) [Abstract]
Tax provision, discontinued operations	$ 0	$ 0
Accumulated other comprehensive income reclassification	$ (42,502)

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Equity - USD ($)	Common Stock [Member]	Additional paid-in capital [Member]	Treasury stock [Member]	Accumulated other comprehensive income [Member]	Retained earnings (accumulated deficit) [Member]	Total
Stockholders' Equity Attributable to Parent, Beginning Balance at Dec. 31, 2013	$ 39,265	$ 11,236,236	$ (3,272,808)	$ 42,502	$ (1,698,671)	$ 6,346,524
Shares, Outstanding, Beginning Balance at Dec. 31, 2013	3,926,491		1,204,252
Share-based compensation - options		33,390				33,390
Issuance of common stock from treasury, shares			(26,100)
Issuance of common stock from treasury		43,631	$ 57,061			100,692
Exercise of warrants from treasury		23,436	$ 81,864			105,300
Exercise of warrants from treasury, shares			(30,000)
Net income (loss)					659,209	659,209
Stockholders' Equity Attributable to Parent, Ending Balance at Dec. 31, 2014	$ 39,265	11,336,693	$ (3,133,883)	42,502	(1,039,462)	7,245,115
Shares, Outstanding, Ending Balance at Dec. 31, 2014	3,926,491		1,148,152
Accumulated comprehensive income from unrealized gains and losses in currency translation		(51)		$ (42,502)		(42,553)
Share-based compensation - options		29,178				29,178
Issuance of common stock from treasury, shares			(23,300)
Issuance of common stock from treasury		15,716	$ 64,387			80,103
Net income (loss)					(429,166)	(429,166)
Stockholders' Equity Attributable to Parent, Ending Balance at Dec. 31, 2015	$ 39,265	$ 11,381,536	$ (3,069,496)		$ (1,468,628)	$ 6,882,677
Shares, Outstanding, Ending Balance at Dec. 31, 2015	3,926,491		1,124,852

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Cash flows from operating activities:
Net income (loss)	$ (429,166)	$ 659,209
Loss (income) from discontinued operations	(362,610)	1,779
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
(Gain) loss on sale of property, plant and equipment	13,320	(21,000)
Depreciation and amortization	1,464,588	1,475,806
Impairment of intangibles	118,318	63,087
Non-cash interest expense	27,683	27,683
Change in allowance for doubtful accounts	15,000	5,000
Share-based compensation expense	29,178	33,390
Changes in operating assets and liabilities:
Accounts receivable	723,394	262,106
Inventories	395,529	(178,950)
Prepaid expenses and other current assets	(94,547)	(6,385)
Other non-current assets	301,522	(384,762)
Accounts payable	(303,768)	(298,875)
Accrued expenses and other current liabilities	(90,426)	(294,351)
Other non-current liabilities	(338,249)	438,114
Net cash provided by (used in) operating activities of continuing operations	1,469,766	1,781,851
Net cash provided by (used in) operating activites of discontinued operations	0	(1,509)
Net cash provided by (used in) operating activities	1,469,766	1,780,342
Cash flows from investing activities:
Purchases of property, plant and equipment	(1,182,541)	(1,514,678)
Proceeds from sale of property, plant and equipment	35,700	24,500
Cash paid for patents and trademarks	(6,176)	(16,566)
Net cash provided by (used in) investing activities from continuing operations	(1,153,017)	(1,506,744)
Net cash provided by (used in) investing activities from discontinued operations	0	0
Net cash provided by (used in) investing activities	(1,153,017)	(1,506,744)
Cash flows from financing activities:
Proceeds from (payments on) revolving line of credit, net	(560,000)	(703,000)
Proceeds from equipment line of credit	752,635	116,905
Payments on term notes payable	(526,594)	(435,372)
Proceeds from warrant exercises	0	105,300
Proceeds from stock option exercises	80,103	100,692
Net cash provided by (used in) financing activities from continuing operations	(253,856)	(815,475)
Net cash provided by (used in) financing activities from discontinued operations	0	0
Net cash provided by (used in) financing activities	(253,856)	(815,475)
Net increase (decrease) in cash and cash equivalents	62,893	(541,877)
Cash and cash equivalents, beginning of period	209,398	751,275
Cash and cash equivalents, end of period	272,291	209,398
Less: cash and cash equivalents of discontinued operations at end of period	0	0
Cash and cash equivalents of continuing operations at end of period	272,291	209,398
Supplemental Cash Flow Information (unaudited)
Cash paid for interest	222,237	228,255
Cash received from tax refunds	0	132
Non-cash activities:
Reclassified assets held for sale	665,000
Equipment line of credit converted to term notes payable	415,785	740,999
Reduction of restricted cash offset by performance guarantee	$ 0	$ 975,430

Consolidated Statements of Cas8

Consolidated Statements of Cash Flows (Additional Information) - USD ($)	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Consolidated Statements of Cash Flows [Abstract]
Cash and cash equivalents, end of period	$ 272,291	$ 209,398	$ 751,275
Less: cash and cash equivalents of discontinued operations at end of period	0	0
Cash and cash equivalents of continuing operations at end of period	$ 272,291	$ 209,398

Description of Business

Description of Business	12 Months Ended
	Dec. 31, 2015
Description of Business [Abstract]
Description of Business	1. De scription of Business Arrhythmia Research Technology ® , Inc., (“ART”), through its wholly-owned subsidiary, Micron Products ® , Inc. ("Micron", and collectively with ART, the "Company") is a diversified contract manufacturing organization (“CMO”) that produces highly-engineered, innovative components requiring precision machining and injection molding. The Company also manufactures components, devices and equipment for military, law enforcement, automotive and consumer products applications. The Company's capabilities include molding and silver plating of medical sensors, thermoplastic injection molding, customer-specific quick-turn orthopedic implant component manufacturing and custom products for military and law enforcement applications. The Company competes globally, with nearly forty percent of its revenue derived from exports. ART was founded in 1986, completed an initial public offering in 1988 and shares have been listed on the NYSE MKT since 1992. Its stock trades under the symbol HRT. The Company has grown organically and through acquisitions. Today, the Company has diversified manufacturing capabilities with the capacity to participate in full product life-cycle activities from early stage development and engineering and prototyping to full scale manufacturing as well as packaging and product fulfillment services. The Company's subsidiary, RMDDxUSA Corp. and its Prince Edward Island subsidiary RMDDx Corporation (collectively "WirelessDx"), discontinued operations in 2012, filed for relief under Chapter 7 (Liquidation) of the United States Bankruptcy Code in May 2014 and in March 2015, the Chapter 7 Order was formally discharged and the case was closed (see Note 12). Operating matters and liquidity The revolver under the Company's credit facility has a maturity date of June 2017 (see Note 5). At December 31, 2015 , the outstanding balance on the revolver was $1,511,495 . The Company believes that cash flows from its operations, together with its existing working capital, the revolver and other resources, will be sufficient to fund operations at current levels and repay debt obligations over the next twelve months and beyond; however, there can be no assurance that the Company will be able to do so.

Accounting Policies

Accounting Policies	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Accounting Policies	2. Accounting Policies Principles of consolidation The consolidated financial statements (the "financial statements") include the accounts of ART, Micron and WirelessDx. WirelessDx is presented herein as discontinued operations. All intercompany balances and transactions have been eliminated in consolidation. Use of estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates. Revenue Recognition Product revenue is recorded when all criteria for revenue recognition have been satisfied, which is generally when goods are shipped to the Company's customers. Product revenue is recognized in the period when persuasive evidence of an arrangement with a customer exists, the products are shipped and title has transferred to the customer, the price is fixed or determined and collection is probable. The Company enters into arrangements containing multiple elements which may include a combination of the sale of molds, tooling, engineering and validation services ("tooling") and production units. The Company has determined that certain tooling arrangements, and the related production units, represent one unit of accounting, based on an assessment of the respective standalone value. When the Company determines that an arrangement represents one unit of accounting, the revenue is deferred over the estimated product life-cycle, based upon historical knowledge of the customer, which is generally three years. The Company carries the sales and tooling costs, associated with the related arrangement, as deferred revenue and other current and non-current assets, respectively, on the Company's balance sheet. As the deferred revenue is amortized to sales, the associated prepaid tooling costs are amortized to cost of sales. The Company cannot effectively predict short-term or long-term production volume in a consistent and meaningful manner due to the nature of these molds and associated products. Therefore, the Company is unable to account for the transactions under the Units of Production method and management has determined the most appropriate amortization method to be the Straight-Line method. The Company may from time to time, at the customer's request, enter into a bill and hold arrangement. The Company evaluates the nature of the arrangement including, but not limited to (i) the customer's business purpose, (ii) the transfer of risk of ownership to the customer and (iii) the segregation of inventory, along with other elements in accordance with relevant accounting guidance to determine the appropriate method of revenue recognition for each arrangement. Revenue for software license sales is recognized when licenses are sold as the revenue cycle is completed with no warranty, returns or technical support to customers. Total revenue from software sales was immaterial in relation to consolidated revenues. Fair value of financial instruments The carrying amount reported in the balance sheets for cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair value due to the immediate or short-term nature of such instruments. The carrying value of debt approximates fair value since it provides for market terms and interest rates. Concentration of credit risk Financial instruments which potentially expose the Company to concentrations of credit risk consist primarily of accounts receivable and cash and cash equivalents. It is the Company’s policy to place its cash in high quality financial institutions. The Company does not believe significant credit risk exists above federally insured limits with respect to these institutions. Accounts receivable are customer obligations due under normal trade terms. A large portion of the Company's products are sold to large diversified medical, military and law enforcement product manufacturers. The Company does not generally require collateral for its sales; however, the Company believes that its terms of sale provide adequate protection against credit risk. While the Company has a strong record of collecting on its receivables, the Company maintains Accounts Receivables insurance in order to mitigate concentration of credit risk where our top five customers in revenue constituted 51% of the AR at December 31, 2015 as compared to 55% at December 31, 2014. During the year ended December 31, 2015 , the Company had net sales to two customers constituting 16% and 13% of total 2015 net sales. Accounts receivable from these two customers at December 31, 2015 was 9% each of the total accounts receivable balance at year end. During the year ended December 31, 2014 , the Company had net sales to four customers constituting 15% , 13% , 12% and 10% , respectively, of total 2014 net sales. Accounts receivable from the four customers at December 31, 2014 was 11% , 9% , 15% and 14% , respectively, of the total accounts receivable balance at year end. Cash and cash equivalents Cash and cash equivalents consist of cash on hand and on deposit in high quality financial institutions with maturities of three months or less at the time of purchase. Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable represent amounts invoiced by the Company. Management maintains an allowance for doubtful accounts based on information obtained regarding individual accounts and historical experience. Amounts deemed uncollectible are written off against the allowance for doubtful accounts. Bad debts have not had a significant impact on the Company’s financial position, results of operations and cash flows. Inventories The Company values its inventory at the lower of average cost, first-in-first-out (FIFO) or net realizable value. The Company reviews its inventory for quantities in excess of production requirements, obsolescence and for compliance with internal quality specifications. Any adjustments to inventory would be equal to the difference between the cost of inventory and the estimated net market value based upon assumptions about future demand, market conditions and expected cost to distribute those products to market. The Company records adjustments to account for potential scrap during normal manufacturing operations or potential obsol esce for slow moving inventory. Property, plant and equipment Property, plant and equipment are recorded at cost and include expenditures which substantially extend their useful lives. Depreciation on property, plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets. Expenditures for maintenance and repairs are charged to earnings as incurred. When equipment is retired or sold, the resulting gain or loss is reflected in earnings. Assets held for sale Property classified as held for sale is measured at the lower of its carrying value or fair value less cost to sell. Gains or losses are recognized for any subsequent changes to fair value less cost to sell; however, gains that may be recognized are limited by cumulative losses previously recognized. Property held for sale is not depreciated. Property is classified as held for sale in the period in which management with the appropriate authority commits to a plan to sell the asset; the asset is available for immediate sale in its present condition subject only to terms that are usual and customary for sales of such assets; an active program to locate a buyer and other actions required to complete the plan of sale have been initiated; the sale of the property or asset within one year is probable and will qualify for accounting purposes as a sale; the asset is being actively marketed for sale at a price that is reasonable in relation to its current fair value; and actions required to complete the plan of sale indicate that it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn. Long-lived assets classified as held for sale are presented separately in the statement of financial position of the current period. Fair value hierarchy The Company groups its assets and liabilities generally measured at fair value in three levels, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value. Level 1 – Valuation is based on quoted prices in active markets for identical assets or liabilities. Valuations are obtained from readily available pricing sources. Level 2 – Valuation is based on observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Valuation is based on unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using unobservable inputs to pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the investment. The Company recognizes transfers between levels at the end of the reporting period. At December 31, 2015, assets held for sale is the only item in the financial statements reflected at fair value. Assets held for sale are considered level 3. The fair value of assets held for sale was determined using the sales price per a purchase and sale agreement less the estimated cost to sell. Long-lived and intangible assets The Company assesses the impairment of long-lived assets and intangible assets with finite lives annually or whenever events or changes in circumstances indicate that the carrying value may not be fully recoverable. Based upon the annual review, the Company recorded impairment charges of $118,318 and $63,087 in 2015 and 2014, respectively. In 2015, the Company reviewed unamortized costs for patents pending. As a result of this review, the Company determined that the patents pending related to the Triggering Recharging and Wireless Transmission of Remote Patient Monitoring Device, as well as the Seed-Beat Selection Method for Signal-Averaged Electrocardiography were no longer patentable and recorded an impairment charge of $103,287 for the full costs of these patents pending. Additionally, after a review of trade names, the Company determined that the Leominster Tool & Die no longer provided any future economic benefit and recorded an impairment charge of $15,031 for the remaining unamortized balance of the trade names. In 2014, the Company reviewed unamortized costs for patents pending. As a result of this review, the Company determined that the patent pending related to the Ambulatory Physiological Monitoring with Remote Analysis were no longer patentable and recorded an impairment charge of $56,237 for the full costs of these patents pending. Additionally, the Company recorded an impairment charge of $6,850 related to its tradename PureTrace, therefore, the total impairment was $63,087 . Intangible assets consist of the following: Estimated December 31, 2015 December 31, 2014 Useful Life Accumulated Accumulated (in years) Gross Amortization Net Gross Amortization Net Patents and trademarks 10 $ 26,290 7,981 $ 18,309 $ 414,436 $ 394,371 $ 20,065 Patents and trademarks pending — 336 336 97,447 — 97,447 Trade names — — 33,250 16,740 16,510 Total intangible assets $ 26,626 $ 7,981 $ 18,645 $ 545,133 $ 411,111 $ 134,022 Amortization expense related to intangible assets, excluding the above noted impairment charge, was $3,235 and $3,974 in 2015 and 2014 , respectively. Estimated future annual amortization expense for currently amortizing intangible assets is expected to approximate $1,756 . Income taxes The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement and tax bases of assets and liabilities using tax rates in effect for the year in which the differences are expected to reverse. The Company follows the provisions of FASB ASC 740, “Accounting for Uncertainty in Income Taxes—An Interpretation of FASB No. 109.” FASB ASC 740 provides detailed guidance for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in the financial statements in accordance with SFAS No. 109. Tax positions must meet a “more-likely-than-not” recognition threshold at the effective date to be recognized upon the adoption of FASB ASC 740 and in subsequent periods. No interest and penalties related to uncertain tax positions were accrued at December 31, 2015. The Company ’s primary operations are located in the US. Tax years ended December 31, 2012 or later remain subject to examination by the IRS and state taxing authori ties. Share-based compensation Share-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the employee’s requisite service period (generally the vesting period of the share-based grant). Comprehensive income In 2015 and 2014, the Company has accumulated other comprehensive income of $0 and $42,502 , respectively. In 2015, the change in accumulated comprehensive income was a result of the 2015 bankruptcy filing of RMDDx USA Corp . Earnings per share data Basic earnings (loss) per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding. The computation of diluted earnings (loss) per share is similar to the computation of basic earnings (loss) per share except that the denominator is increased to include the average number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued. In addition, the numerator is adjusted for any changes in net income (loss) that would result from the assumed conversions of those potential shares. Research and development Research and development expenses include costs directly attributable to conducting research and development programs primarily related to the development of a unique process to improve silver coating during the manufacturing processes, including the design and testing of specific process improvements for certain medical device components. Such costs include salaries, payroll taxes, employee benefit costs, materials, supplies, depreciation on research equipment, and services provided by outside contractors. All costs associated with research and development programs are expensed as incurred. Recently Issued Accounting Pronouncements In the normal course of business, management evaluates all new accounting pronouncements issued by the FASB, SEC, Emerging Issues Task Force (“EITF”), or other authoritative accounting bodies to determine the potential impact they may have on the Company’s Consolidated Financial Statements. Based upon this review, except as noted below, management does not expect any of the recently issued accounting pronouncements, which have not already been adopted, to have a material impact on the Company’s Consolidated Financial Statements. In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842),” which requires companies to recognize all leases as assets and liabilities on the consolidated balance sheet. This ASU retains a distinction between finance leases and operating leases, and the classification criteria for distinguishing between finance leases and operating leases are substantially similar to the classification criteria for distinguishing between capital leases and operating leases in the current accounting literature. The result of retaining a distinction between finance leases and operating leases is that under the lessee accounting model in Topic 842, the effect of leases in a consolidated statement of comprehensive income and a consolidated statement of cash flows is largely unchanged from previous GAAP. The amendments in this ASU are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Earlier application is permitted. The Company is currently evaluating the impact that the adoption of this ASU will have on its Consolidated Financial Statements. In July 2015, the FASB issued ASU No. 2015-11, “Simplifying the Measurement of Inventory,” which simplifies the subsequent measurement of inventory by requiring inventory to be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. This ASU is effective for public business entities for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. The Company is currently assessing the impact of adopting this ASU on its Consolidated Financial Statements. In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers.” The core principle behind ASU No. 2014-09 is that an entity should recognize revenue in an amount that reflects the consideration to which the entity expects to be entitled in exchange for delivering goods and services. This model involves a five-step process that includes identifying the contract with the customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations in the contract and recognizing revenue when the entity satisfies the performance obligations. This ASU allows two methods of adoption; a full retrospective approach where historical financial information is presented in accordance with the new standard, and a modified retrospective approach where this ASU is applied to the most current period presented in the financial statements. In August 2015, the FASB issued ASU No 2015-14 “Revenue from Contracts with Customers: Deferral of the Effective Date,” which deferred the effective date of ASU 2014-09 to annual reporting periods beginning after December 15, 2017, with earlier application permitted as of annual reporting periods beginning after December 15, 2016. The Company is currently assessing the financial impact of adopting ASU 2014-09 and the methods of adoption; however, given the scope of the new standard, the Company is currently unable to provide a reasonable estimate regarding the financial impact or which method of adoption will be elected. In April 2014, the FASB issued ASU No. 2014-08, “Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity,” which amends the definition of a discontinued operation and requires entities to provide additional disclosures about disposal transactions that do not meet the discontinued operations criteria. The revised ASU changes how entities identify and disclose information about disposal transactions under U.S. GAAP. This ASU is effective prospectively for all disposals (except disposals classified as held for sale before the adoption date) or components initially classified as held for sale in periods beginning on or after December 15, 2014. This ASU is applicable for disposal transactions, if any, that the Company enters into after January 2, 2015. This ASU did not materially impact the Company’s Consolidated Financial Statements. Reclassification of prior period balances Amounts in prior year financial statements are reclassified when necessary to conform to the current year presentation.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2015
Inventories [Abstract]
Inventories	3. Inventories Inventories consist of the following: December 31, December 31, 2015 2014 Raw materials $ 775,427 $ 873,306 Work-in-process 265,113 370,220 Finished goods 1,078,172 1,270,715 Total $ 2,118,712 $ 2,514,241 The total cost of silver in our inventory as raw materials, in work-in-process or as a plated surface on finished goods had an estimated cost of $313,738 and $439,800 in 2015 and 2014 , respectively.

Property, Plant and Equipment,

Property, Plant and Equipment, Net	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment, Net [Abstract]
Property, Plant and Equipment, Net	4. Property, Plant and Equipment, Net Property, plant and equipment , net consist of the following: Asset Lives December 31, December 31, (in years) 2015 2014 Machinery and equipment 3 to 15 $ 15,168,377 $ 14,608,949 Building and improvements 5 to 25 3,978,387 4,360,114 Vehicles 3 to 5 90,713 90,713 Furniture, fixtures, computers and software 3 to 5 1,437,692 1,349,931 Land — 202,492 Construction in progress 682,069 568,234 Total property, plant and equipment 21,357,238 21,180,433 Less: accumulated depreciation (14,731,169) (13,561,532) Property, plant and equipment, net $ 6,626,069 $ 7,618,901 For the year ended December 31, 2015 , the Company recorded $1,461,353 of depreciation expense compared to $1,471,832 for the year ended December 31, 2014 . There are no commitments related to the completion of construction in process as of December 31, 2015 . On December 4, 2015, t he Company entered into a Letter of Intent to sell the two unoccupied buildings , with a total of approximately 52,000 square feet , and land, at its Fitchburg, Massachusetts campus . Subsequently, on January 13, 2016, the Company entered into a Purchase and Sale Agreement for these buildings. As t hese buildings are under agreement to be sold , they have been classified as Assets H eld for S ale at December 31, 2015 . The carrying value of the properties ($665,000) approximated the fair value less the cost to sell. The Company expects the sale of the properties to be completed by the end of 2016 and does not expected any material impact on the statement of operations.

Debt

Debt	12 Months Ended
	Dec. 31, 2015
Debt [Abstract]
Debt	5. Debt The following tables set forth the items which comprise debt for the Company: December 31, December 31, 2015 2014 Revolving line of credit $ 1,511,495 $ 2,071,495 Equipment line of credit $ 336,850 $ — Subordinated promissory notes $ 473,135 $ 445,452 Term notes payable: Commercial term loan $ 714,175 $ 1,009,977 Equipment term loans 879,898 640,734 Equipment notes 116,214 170,385 Total term notes payable $ 1,710,287 $ 1,821,096 Total Debt $ 4,031,767 $ 4,338,043 Bank Debt The revolving line of credit (the "revolver"), commercial term loan, two equipment term loans and an equipment line of credit are all under the terms of a multi-year credit facility with a bank as detailed below. The debt is secured by substantially all assets of the Company with the exception of real property. Revolver The revolver provides for borrowings up to 80% of eligible accounts receivable and 50% of eligible raw materials inventory. The interest rate on the revolver is calculated at the bank's prime rate plus 0.25% ( 3.75% at December 31, 2015 ). The revolver has a maturity date of June 201 7 . Amounts available to borrow under the revolver are $917,830 at December 31, 2015 . Commercial term loan The commercial term loan has a five year term with a maturity date of March 2018. The interest rate on the loan is a fixed 4.25% per annum and the loan requires monthly payments of principal and interest of approximately $28,000 . Equipment line of credit and equipment term loan s On March 29, 2013, the Company entered into an equipment line of credit that allowed for advances of up to $1.0 million and included a one -year draw period during which payments were interest only. The draw period ended March 29, 2014 and the then outstanding balance on the equipment line of credit of $740,999 was converted to an equipment term loan with a five -year term, maturing on of March 29, 2019 . The equipment term loan requires monthly payments of approximately $14,000 , consisting of principal and interest at a fixed rate of 4.65% . On June 26, 2014, the Company entered into an equipment line of credit that allowed for advances of up to $1.0 million and included a one -year draw period during which payments were interest only. The draw period ended June 26, 2015 and the then outstanding balance on the equipment line of credit of $415,785 was converted to an equipment term loan with a five -year term, maturing on of June 26, 2020 . The equipment term loan requires monthly payments of approximately $8,000 , consisting of principal and interest at a fixed rate of 4.67% . On June 19, 2015, the Company entered into a new equipment line of credit for $1.0 million under the Company's multi-year credit facility. At December 31, 2015, the Company has drawn $336,850 on the new equipment line of credit. The term of this equipment line of credit is six years, maturing on June 19, 2021 , inclusive of a maximum one -year draw period. Repayment shall consist of monthly interest only payments, equal to the bank's prime rate plus 0.25% as to each advance commencing on the date of the loan through the earlier of: (i) one year from the date of the loan or (ii) the date upon which the equipment line of credit is fully advanced (the “Conversion Date”). On the Conversion Date, principal and interest payments will be due and payable monthly in an amount sufficient to pay the loan in full based upon an amortization schedule commensurate with the remaining term of the loan. Bank covenants The bank facility contains both financial and non-financial covenants. The financial covenants include maintaining certain debt coverage and leverage ratios. The non-financial covenants relate to various matters including notice prior to executing further borrowings and security interests, mergers or consolidations, acquisitions, guarantees, sales of assets other than in the normal course of business, leasing, changes in ownership and payment of dividends. The Company was in compliance with all bank covenants as of December 31, 2015 . Other debt Equipment notes In January 2013, the Company entered into two equipment notes totaling $272,500 with a financing company to acquire production equipment. The notes bear interest at 4.66% and require monthly payments of principal and interest totaling approximately $5,000 over the term of five years. Subordinated promissory notes In December 2013, the Company completed a private offering in which the Company sold an aggregate of $500,000 in subordinated promissory notes. The notes are unsecured and required quarterly interest-only payments at a rate of 10% per annum for the first two years, increasing to 12% per annum in December 2015. The notes mature in December 2016 at which point the outstanding balance is due in full. The subordinated promissory notes may be prepaid by the Company at any time following the first anniversary thereof without penalty. The notes are subordinated to all indebtedness of the Company pursuant to its March 2013 multi-year bank credit facility. In connection with the subordinated promissory notes, the Company issued warrants to purchase the Company's common stock (see Note 9). In order to account for the subordinated notes payable and warrants, the Company allocated the proceeds between the notes and warrants on a relative fair value basis. As a result, the Company allocated $416,950 to the notes and $83,050 to the warrants. The total discount on the notes is being recognized as non-cash interest expense over the term of the notes. In the years ended December 31, 2015 and 2014 the Company recorded $27,683 per year of non-cash interest expense related to the amortization of the discount. The unamortized discount which is net against the outstanding balance of the subordinated promissory notes is $26,865 at December 31, 2015. Future maturities of debt for the years ending December 31 are as follows: 2016 2017 2018 2019 2020 Thereafter Total Revolver $ — $ 1,511,495 $ — $ — $ — — $ 1,511,495 Subordinated promissory notes 500,000 — — — — — 500,000 Term debt and equipment notes 625,353 679,808 394,214 198,707 118,175 30,880 2,047,137 Total $ 1,125,353 $ 2,191,303 $ 394,214 $ 198,707 $ 118,175 30,880 $ 4,058,632

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2015
Income Taxes [Abstract]
Income Taxes	6. Income Taxes The income tax provision consists of the following: Years Ended December 31, 2015 2014 Current: Federal $ — $ — State 932 2,168 Total current income taxes 932 2,168 Deferred: Federal — — State — — Total deferred income taxes — — Total income tax provision $ 932 $ 2,168 The components of deferred income taxes are as follows: Years Ended December 31, 2015 2014 Deferred income taxes: Current deferred tax assets: Inventories $ 93,600 $ 188,300 Bad debt reserve 23,700 65,200 Accrued expenses — 25,100 Total current deferred tax assets 117,300 278,600 Long-term deferred tax assets: Net operating loss carryforwards 3,221,000 2,982,100 Foreign net operating loss carryforwards — 291,100 Federal and state tax credit carryforwards 608,000 421,700 Patents and intangibles 68,100 73,000 Stock compensation 89,800 89,700 Other long term 45,500 142,100 Total long-term deferred tax assets 4,032,400 3,999,700 Total deferred tax assets 4,149,700 4,278,300 Current deferred tax liabilities: Prepaid expenses (64,600) (59,900) Long-term deferred tax liabilities: Property, plant and equipment (612,800) (976,400) Total deferred tax liabilities (677,400) (1,036,300) Deferred tax valuation allowance (3,472,300) (3,242,000) Net deferred tax assets (liabilities) $ — $ — In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax-planning strategies in making this asse ssment. As of December 31, 2015, the company continues to maintain a valuation allowance against all of its domestic and foreign deferred tax assets. For the year ended December 31, 2015 , the Compan y has federal and state net operating loss carryforwards totaling $8,195,636 and $8,231,513 respecti vely, which begin to expire in 203 1 . The Company also had federal and state tax credit carryovers of $361,000 and $380,000 , respectively. The federal and state credits begin to expire in 202 7 and 201 6 , respectively. The Company files a consolidated federal income tax return. The actual income tax provision differs from applying the Federal statutory income tax rate ( 34% ) to the pre-income tax loss from continuing operations as follows: Years Ended December 31, 2015 2014 Tax (benefit) provision computed at statutory rate $ (145,442) $ 224,867 Increases (reductions) due to: Change in valuation allowance 230,300 (136,268) State income taxes, net of federal benefit 615 23,475 Permanent differences 479 14,561 Tax credits (federal and state) (108,194) (6,630) Utilization of deferred taxes previously reserved — (117,837) Differences on prior returns (federal and state) 23,174 — Income tax provision $ 932 $ 2,168

Employee Benefit Plans

Employee Benefit Plans	12 Months Ended
	Dec. 31, 2015
Employee Benefit Plans [Abstract]
Employee Benefit Plans	7. Employee Benefit Plans The Company sponsors an Employee Savings and Investment Plan under Section 401(k) of the Internal Revenue Code covering all eligible employees of the Company. Employees can contribute up to 90% of their eligible compensation to the maximum allowable by the IRS. The Company’s matching contributions are at the discretion of the Company. The Company’s matching contributions in 2015 and 2014 we re $47,858 and $46,958 , respectiv ely.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies [Abstract]
Commitments and Contingencies	8. Commitments and Contingencies Legal matters In the ordinary course of its business, the Company is involved in various legal proceedings involving a variety of matters. The Company does not believe there are any pending legal proceedings that will have a material impact on the Company’s financial position or results of operations. Operating lease agreements In 2014 , the Company entered into two operating leases for office equipment. The leases require future minimum annual lease payments o f $7,287 and $1,602 for fiscal years 2016 and 2017 , respec tively.

Shareholders' Equity

Shareholders' Equity	12 Months Ended
	Dec. 31, 2015
Shareholders' Equity [Abstract]
Shareholders' Equity	9. Shareholders’ equity Common stock In 2015, 23,300 shares were issued out of treasury as a result of the exercise of stock options and no warrants were exercised. In 2014, 26,100 and 30,000 shares were issued as a result of the exercise of stock options and warrants, respectively (see below). No dividends were declared or paid in 201 5 or 201 4 . Warrants In connection with the subordinated promissory notes issued in December 2013 (see Note 5), the Company issued warrants to purchase 100,000 shares of the Company’s common stock. The warrants are exercisable during the period commencing six months after issuance and for three years from issuance, at an exercise price equal to $3.51 per share, namely, the closing market price of the Company’s common stock on the day prior to the closing date of the offering. The warrants expire in December 2016. During 2015, there were no warrants exercised. During 2014, the Company received proceeds of $105,300 from the exercise of 30,000 warrants. As of December 31, 2015, 70,000 warrants remain unexercised. Stock options and Share-Based Incentive Plan In March 2010, the Company's Board of Directors adopted the Arrhythmia Research Technology, Inc. 2010 Equity Incentive Plan (the “2010 Plan”). The 2010 Plan authorizes the issuance of an aggregate of 500,000 shares. The Company's 2001 Stock Option Plan (the "2001 Plan"), which expired in 2011, will continue to govern outstanding options but no further options will be granted under the 2001 Plan. The Company now has one plan providing the Company flexibility to award a mix of stock options, equity incentive grants, performance awards and other types of stock-based compensation to certain eligible employees, non-employee directors, or consultants and under which an aggregate of 500,000 shares have been reserved for such grants. The options granted have either six or ten year contractual terms that vest annually over a five -year term. At December 31, 2015 , there were options to acquire an aggregate of 184,500 shares outstanding; 15,000 from the 2001 Plan and 169,500 from the 2010 Plan. At December 31, 2015 , there were 318,000 shares available fo r future grants under the 2010 Plan, after giving effect to shares which became available for reissuance due to expired or forfeited options. The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model that uses the assumptions noted in the following table. Expected volatilities are based on historical volatility of the Common Stock using historical periods consistent with the expected term of the options. The expected term of options granted under the Company’s equity incentive plan, all of which qualify as “plain vanilla,” is based on the average of the contractual term and the vesting period as permitted under SEC Staff Accounting Bulletin Nos. 107 and 110. The risk-free rate is based on the yield of a U.S. Treasury security with a term consistent with the option. During 2015 and 2014 there were 62,500 and 7,500 new option grants, respectively. The assumptions used to measure the fair value of option grants in 2015 and 2014 were as follows: Years Ended December 31, 2015 2014 Expected option term 4.0 to 6.5 6.5 Expected volatility factor 23.8% to 26.7% 27% Risk-free rate .90% to 1.28% 0.96% Expected annual dividend yield —% —% The following table sets forth the stock option transactions for the year ended December 31, 201 5 : Weighted Weighted average Average remaining Aggregate Number of Exercise contractual Intrinsic options Price term (in years) Value Outstanding at December 31, 2014 165,800 $ 5.58 6.09 $ 305,124 Granted 62,500 6.36 Exercised (23,300) 3.44 Forfeited (19,500) 4.74 Expired (1,000) 3.67 Outstanding at December 31, 2015 184,500 6.21 6.80 $ 235,293 Exercisable at December 31, 2015 83,500 $ 6.60 4.73 $ 106,565 Exercisable at December 31, 2014 74,400 $ 6.07 4.75 $ 119,342 The total intrinsic value of options exercised during 2015 and 2014 were $60,197 and $80,800 , respectively. For the years ended December 31, 2015 and 2014 , share-based compensation expense related to stock options and the non-cash issuance of common stock amounted to $29,178 and $33,390 , respectively, and is included in general and administrative expenses. As of December 31, 2015 and 2014 , there was $134,160 and $86,896 of unrecognized compensation costs, respectively, related to non-vested share-based compensation arrangements granted under the stock option plan. This cost is expected to be recognized over a weighted average period of 3.2 years. The weighted average grant date fair value of options issued in 2015 was $1.66 .

Earnings per share

Earnings per share	12 Months Ended
	Dec. 31, 2015
Earnings per Share [Abstract]
Earnings per Share	10. Earnings per share Basic earnings (loss) per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding. The computation of diluted earnings (loss) per share is similar to the computation of basic earnings (loss) per share except that the denominator is increased to include the average number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued. In addition, the numerator is adjusted for any changes in net income (loss) that would result from the assumed conversions of those potential shares. As of December 31, 2015 there were options to purchase 184,500 shares and warrants to purchase 70,000 shares of the Company's common stock outstanding, all of which were anti-dilutive. Therefore, none of these options or warrants were included in the calculation of loss per share in 2015 . As of December 31, 201 4 there were options to purchase 165,800 shares and warrants to purchase 70,000 shares of the Company's common stock outstanding. As of December 31, 2014 , 47,500 of the options to purchase, and none of the warrants, were anti-dilutive and therefore not included in the calculation of earnings per share in 2014. The following table shows the calculation of earnings (loss) per share for the years ended December 31, 2015 and 2014 : Years Ended December 31, 2015 2014 Income (loss) from continuing operations $ (791,776) $ 660,988 Income (loss) from discontinued operations, net of tax 362,610 (1,779) Net income (loss) available to common shareholders $ (429,166) $ 659,209 Basic EPS: Weighted average common shares outstanding 2,784,757 2,742,080 Earnings (loss) per share - basic Continuing operations $ (0.28) $ 0.24 Discontinued operations 0.13 — Consolidated basic EPS $ (0.15) $ 0.24 Diluted EPS: Weighted average common shares outstanding 2,784,757 2,742,080 Assumed conversion of net common shares issuable under stock option plans — 91,889 Assumed conversion of net common shares issuable under warrants — 29,129 Weighted average common and common equivalent shares outstanding, diluted 2,784,757 2,863,098 Earnings (loss) per share - diluted Continuing operations $ (0.28) $ 0.23 Discontinued operations 0.13 — Consolidated diluted EPS $ (0.15) $ 0.23

Industry and Geographic Segment

Industry and Geographic Segments	12 Months Ended
	Dec. 31, 2015
Industry and Geographic Segments [Abstract]
Industry and Geographic Segments	11. Industry and Geographic Segments The Company’s Chief Operating and Decision Maker ("CODM") manages the operations and reviews the results of operations as a single reporting unit. While the Company operates its business as one segment, the Company has diversified manufacturing capabilities as evidenced by its product offerings across several industry categories support ing customers around the globe. The following table sets forth, for the periods indicated, the consolidated revenue and percentages of revenue from continuing operations derived from the sales of the Company's products and services in certain industries. Revenue for the Years Ended December 31, 2015 % 2014 % Medical $ 16,770,788 78 $ 19,714,328 82 Automotive/Industrial 2,839,926 13 1,753,946 7 Military and Law Enforcement 943,603 4 1,358,568 6 Consumer Products 647,190 4 852,030 3 Other 293,677 1 391,420 2 Total $ 21,495,184 100 $ 24,070,292 100 The following table sets forth, for the periods indicated, the consolidated revenue and percentages of revenue from continuing operations derived from the sales of all of the Company's products and services by geographic market. Revenue for the Years Ended December 31, 2015 % 2014 % United States $ 13,199,188 61 $ 13,050,717 54 Asia 4,774,910 22 5,168,283 21 Europe 1,662,318 9 1,344,098 6 Canada 1,607,445 7 3,791,229 16 Other 251,323 1 715,965 3 Total $ 21,495,184 100 $ 24,070,292 100

Discontinued Operations

Discontinued Operations	12 Months Ended
	Dec. 31, 2015
Discontinued Operations [Abstract]
Discontinued Operations	12. Discontinued Operations The Company's subsidiary, RMDDxUSA Corp. and its Prince Edward Island subsidiary RMDDx Corporation (collectively "WirelessDx"), discontinued operations 2012, filed for relief under Chapter 7 (Liquidation) of the United States Bankruptcy Code in 2014 and on March 20, 2015, the Chapter 7 Order was formally discharged and the case was closed. For 2015 net income of $362,610 was recorded from discontinued operations as a result of the write-off of the remaining liabilities of $320,056 and the reversal of accumulated other comprehensive income of $42, 553 from cumulative translation adjustments from RMDDx Corporation. The assets and liabilities of the discontinued operations are listed below: Years Ended December 31, 2015 2014 Cash $ — $ — Total current assets from discontinued operations — — Total assets from discontinued operations $ — $ — Accounts payable and accrued expenses $ — $ 320,056 Total current liabilities from discontinued operations — 320,056 Total liabilities from discontinued operations $ — $ 320,056

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	13. Subsequent Events Assets Held for Sale In January 2016 the Company entered into an agreement to sell two unoccupied buildings and land on its campus in Fitchburg, Massachusetts. These assets have been classified as Assets Held for Sale at December 31, 2015. The carrying value of the properties approximates the fair value less the cost to sell. The Company expects the sale of the properties to be completed by the end of 2016 and does not expect any material impact on the statement of operations. Appointment of Director On February 1, 2016 , the Company's Board of Directors appointed Mr. Bryan S . Ganz a director of the Company, effective February 1, 2016 . A description of Mr. Ganz’s background can be found in the Current Report on Form 8-K filed on February 5 , 201 6 .

Accounting Policies (Policies)

Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Principles of consolidation	Principles of consolidation The consolidated financial statements (the "financial statements") include the accounts of ART, Micron and WirelessDx. WirelessDx is presented herein as discontinued operations. All intercompany balances and transactions have been eliminated in consolidation.
Use of estimates	Use of estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.
Revenue Recognition	Revenue Recognition Product revenue is recorded when all criteria for revenue recognition have been satisfied, which is generally when goods are shipped to the Company's customers. Product revenue is recognized in the period when persuasive evidence of an arrangement with a customer exists, the products are shipped and title has transferred to the customer, the price is fixed or determined and collection is probable. The Company enters into arrangements containing multiple elements which may include a combination of the sale of molds, tooling, engineering and validation services ("tooling") and production units. The Company has determined that certain tooling arrangements, and the related production units, represent one unit of accounting, based on an assessment of the respective standalone value. When the Company determines that an arrangement represents one unit of accounting, the revenue is deferred over the estimated product life-cycle, based upon historical knowledge of the customer, which is generally three years. The Company carries the sales and tooling costs, associated with the related arrangement, as deferred revenue and other current and non-current assets, respectively, on the Company's balance sheet. As the deferred revenue is amortized to sales, the associated prepaid tooling costs are amortized to cost of sales. The Company cannot effectively predict short-term or long-term production volume in a consistent and meaningful manner due to the nature of these molds and associated products. Therefore, the Company is unable to account for the transactions under the Units of Production method and management has determined the most appropriate amortization method to be the Straight-Line method. The Company may from time to time, at the customer's request, enter into a bill and hold arrangement. The Company evaluates the nature of the arrangement including, but not limited to (i) the customer's business purpose, (ii) the transfer of risk of ownership to the customer and (iii) the segregation of inventory, along with other elements in accordance with relevant accounting guidance to determine the appropriate method of revenue recognition for each arrangement. Revenue for software license sales is recognized when licenses are sold as the revenue cycle is completed with no warranty, returns or technical support to customers. Total revenue from software sales was immaterial in relation to consolidated revenues.
Fair value of financial instruments	Fair value of financial instruments The carrying amount reported in the balance sheets for cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair value due to the immediate or short-term nature of such instruments. The carrying value of debt approximates fair value since it provides for market terms and interest rates.
Concentration of credit risk	Concentration of credit risk Financial instruments which potentially expose the Company to concentrations of credit risk consist primarily of accounts receivable and cash and cash equivalents. It is the Company’s policy to place its cash in high quality financial institutions. The Company does not believe significant credit risk exists above federally insured limits with respect to these institutions. Accounts receivable are customer obligations due under normal trade terms. A large portion of the Company's products are sold to large diversified medical, military and law enforcement product manufacturers. The Company does not generally require collateral for its sales; however, the Company believes that its terms of sale provide adequate protection against credit risk. While the Company has a strong record of collecting on its receivables, the Company maintains Accounts Receivables insurance in order to mitigate concentration of credit risk where our top five customers in revenue constituted 51% of the AR at December 31, 2015 as compared to 55% at December 31, 2014. During the year ended December 31, 2015 , the Company had net sales to two customers constituting 16% and 13% of total 2015 net sales. Accounts receivable from these two customers at December 31, 2015 was 9% each of the total accounts receivable balance at year end. During the year ended December 31, 2014 , the Company had net sales to four customers constituting 15% , 13% , 12% and 10% , respectively, of total 2014 net sales. Accounts receivable from the four customers at December 31, 2014 was 11% , 9% , 15% and 14% , respectively, of the total accounts receivable balance at year end.
Cash and cash equivalents	Cash and cash equivalents Cash and cash equivalents consist of cash on hand and on deposit in high quality financial institutions with maturities of three months or less at the time of purchase.
Accounts receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable represent amounts invoiced by the Company. Management maintains an allowance for doubtful accounts based on information obtained regarding individual accounts and historical experience. Amounts deemed uncollectible are written off against the allowance for doubtful accounts. Bad debts have not had a significant impact on the Company’s financial position, results of operations and cash flows.
Inventories	Inventories The Company values its inventory at the lower of average cost, first-in-first-out (FIFO) or net realizable value. The Company reviews its inventory for quantities in excess of production requirements, obsolescence and for compliance with internal quality specifications. Any adjustments to inventory would be equal to the difference between the cost of inventory and the estimated net market value based upon assumptions about future demand, market conditions and expected cost to distribute those products to market. The Company records adjustments to account for potential scrap during normal manufacturing operations or potential obsol esce for slow moving inventory.
Property, plant and equipment	Property, plant and equipment Property, plant and equipment are recorded at cost and include expenditures which substantially extend their useful lives. Depreciation on property, plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets. Expenditures for maintenance and repairs are charged to earnings as incurred. When equipment is retired or sold, the resulting gain or loss is reflected in earnings.
Assets held for sale	Assets held for sale Property classified as held for sale is measured at the lower of its carrying value or fair value less cost to sell. Gains or losses are recognized for any subsequent changes to fair value less cost to sell; however, gains that may be recognized are limited by cumulative losses previously recognized. Property held for sale is not depreciated. Property is classified as held for sale in the period in which management with the appropriate authority commits to a plan to sell the asset; the asset is available for immediate sale in its present condition subject only to terms that are usual and customary for sales of such assets; an active program to locate a buyer and other actions required to complete the plan of sale have been initiated; the sale of the property or asset within one year is probable and will qualify for accounting purposes as a sale; the asset is being actively marketed for sale at a price that is reasonable in relation to its current fair value; and actions required to complete the plan of sale indicate that it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn. Long-lived assets classified as held for sale are presented separately in the statement of financial position of the current period.
Fair value heirarchy	Fair value hierarchy The Company groups its assets and liabilities generally measured at fair value in three levels, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value. Level 1 – Valuation is based on quoted prices in active markets for identical assets or liabilities. Valuations are obtained from readily available pricing sources. Level 2 – Valuation is based on observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Valuation is based on unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using unobservable inputs to pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the investment. The Company recognizes transfers between levels at the end of the reporting period. At December 31, 2015, assets held for sale is the only item in the financial statements reflected at fair value. Assets held for sale are considered level 3. The fair value of assets held for sale was determined using the sales price per a purchase and sale agreement less the estimated cost to sell.
Long-lived and intangible assets	Long-lived and intangible assets The Company assesses the impairment of long-lived assets and intangible assets with finite lives annually or whenever events or changes in circumstances indicate that the carrying value may not be fully recoverable. Based upon the annual review, the Company recorded impairment charges of $118,318 and $63,087 in 2015 and 2014, respectively. In 2015, the Company reviewed unamortized costs for patents pending. As a result of this review, the Company determined that the patents pending related to the Triggering Recharging and Wireless Transmission of Remote Patient Monitoring Device, as well as the Seed-Beat Selection Method for Signal-Averaged Electrocardiography were no longer patentable and recorded an impairment charge of $103,287 for the full costs of these patents pending. Additionally, after a review of trade names, the Company determined that the Leominster Tool & Die no longer provided any future economic benefit and recorded an impairment charge of $15,031 for the remaining unamortized balance of the trade names. In 2014, the Company reviewed unamortized costs for patents pending. As a result of this review, the Company determined that the patent pending related to the Ambulatory Physiological Monitoring with Remote Analysis were no longer patentable and recorded an impairment charge of $56,237 for the full costs of these patents pending. Additionally, the Company recorded an impairment charge of $6,850 related to its tradename PureTrace, therefore, the total impairment was $63,087 . Intangible assets consist of the following: Estimated December 31, 2015 December 31, 2014 Useful Life Accumulated Accumulated (in years) Gross Amortization Net Gross Amortization Net Patents and trademarks 10 $ 26,290 7,981 $ 18,309 $ 414,436 $ 394,371 $ 20,065 Patents and trademarks pending — 336 336 97,447 — 97,447 Trade names — — 33,250 16,740 16,510 Total intangible assets $ 26,626 $ 7,981 $ 18,645 $ 545,133 $ 411,111 $ 134,022 Amortization expense related to intangible assets, excluding the above noted impairment charge, was $3,235 and $3,974 in 2015 and 2014 , respectively. Estimated future annual amortization expense for currently amortizing intangible assets is expected to approximate $1,756 .
Income taxes	Income taxes The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement and tax bases of assets and liabilities using tax rates in effect for the year in which the differences are expected to reverse. The Company follows the provisions of FASB ASC 740, “Accounting for Uncertainty in Income Taxes—An Interpretation of FASB No. 109.” FASB ASC 740 provides detailed guidance for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in the financial statements in accordance with SFAS No. 109. Tax positions must meet a “more-likely-than-not” recognition threshold at the effective date to be recognized upon the adoption of FASB ASC 740 and in subsequent periods. No interest and penalties related to uncertain tax positions were accrued at December 31, 2015. The Company ’s primary operations are located in the US. Tax years ended December 31, 2012 or later remain subject to examination by the IRS and state taxing authori ties.
Share-based compensation	Share-based compensation Share-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the employee’s requisite service period (generally the vesting period of the share-based grant).
Comprehensive income	Comprehensive income In 2015 and 2014, the Company has accumulated other comprehensive income of $0 and $42,502 , respectively. In 2015, the change in accumulated comprehensive income was a result of the 2015 bankruptcy filing of RMDDx USA Corp .
Earnings per share data	Earnings per share data Basic earnings (loss) per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding. The computation of diluted earnings (loss) per share is similar to the computation of basic earnings (loss) per share except that the denominator is increased to include the average number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued. In addition, the numerator is adjusted for any changes in net income (loss) that would result from the assumed conversions of those potential shares.
Research and development	Research and development Research and development expenses include costs directly attributable to conducting research and development programs primarily related to the development of a unique process to improve silver coating during the manufacturing processes, including the design and testing of specific process improvements for certain medical device components. Such costs include salaries, payroll taxes, employee benefit costs, materials, supplies, depreciation on research equipment, and services provided by outside contractors. All costs associated with research and development programs are expensed as incurred.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In the normal course of business, management evaluates all new accounting pronouncements issued by the FASB, SEC, Emerging Issues Task Force (“EITF”), or other authoritative accounting bodies to determine the potential impact they may have on the Company’s Consolidated Financial Statements. Based upon this review, except as noted below, management does not expect any of the recently issued accounting pronouncements, which have not already been adopted, to have a material impact on the Company’s Consolidated Financial Statements. In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842),” which requires companies to recognize all leases as assets and liabilities on the consolidated balance sheet. This ASU retains a distinction between finance leases and operating leases, and the classification criteria for distinguishing between finance leases and operating leases are substantially similar to the classification criteria for distinguishing between capital leases and operating leases in the current accounting literature. The result of retaining a distinction between finance leases and operating leases is that under the lessee accounting model in Topic 842, the effect of leases in a consolidated statement of comprehensive income and a consolidated statement of cash flows is largely unchanged from previous GAAP. The amendments in this ASU are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Earlier application is permitted. The Company is currently evaluating the impact that the adoption of this ASU will have on its Consolidated Financial Statements. In July 2015, the FASB issued ASU No. 2015-11, “Simplifying the Measurement of Inventory,” which simplifies the subsequent measurement of inventory by requiring inventory to be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. This ASU is effective for public business entities for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. The Company is currently assessing the impact of adopting this ASU on its Consolidated Financial Statements. In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers.” The core principle behind ASU No. 2014-09 is that an entity should recognize revenue in an amount that reflects the consideration to which the entity expects to be entitled in exchange for delivering goods and services. This model involves a five-step process that includes identifying the contract with the customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations in the contract and recognizing revenue when the entity satisfies the performance obligations. This ASU allows two methods of adoption; a full retrospective approach where historical financial information is presented in accordance with the new standard, and a modified retrospective approach where this ASU is applied to the most current period presented in the financial statements. In August 2015, the FASB issued ASU No 2015-14 “Revenue from Contracts with Customers: Deferral of the Effective Date,” which deferred the effective date of ASU 2014-09 to annual reporting periods beginning after December 15, 2017, with earlier application permitted as of annual reporting periods beginning after December 15, 2016. The Company is currently assessing the financial impact of adopting ASU 2014-09 and the methods of adoption; however, given the scope of the new standard, the Company is currently unable to provide a reasonable estimate regarding the financial impact or which method of adoption will be elected. In April 2014, the FASB issued ASU No. 2014-08, “Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity,” which amends the definition of a discontinued operation and requires entities to provide additional disclosures about disposal transactions that do not meet the discontinued operations criteria. The revised ASU changes how entities identify and disclose information about disposal transactions under U.S. GAAP. This ASU is effective prospectively for all disposals (except disposals classified as held for sale before the adoption date) or components initially classified as held for sale in periods beginning on or after December 15, 2014. This ASU is applicable for disposal transactions, if any, that the Company enters into after January 2, 2015. This ASU did not materially impact the Company’s Consolidated Financial Statements.
Reclassification of prior period balances	Reclassification of prior period balances Amounts in prior year financial statements are reclassified when necessary to conform to the current year presentation.

Accounting Policies (Tables)

Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Intangibles Assets, Net	Estimated December 31, 2015 December 31, 2014 Useful Life Accumulated Accumulated (in years) Gross Amortization Net Gross Amortization Net Patents and trademarks 10 $ 26,290 7,981 $ 18,309 $ 414,436 $ 394,371 $ 20,065 Patents and trademarks pending — 336 336 97,447 — 97,447 Trade names — — 33,250 16,740 16,510 Total intangible assets $ 26,626 $ 7,981 $ 18,645 $ 545,133 $ 411,111 $ 134,022

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2015
Inventories [Abstract]
Inventories, net	December 31, December 31, 2015 2014 Raw materials $ 775,427 $ 873,306 Work-in-process 265,113 370,220 Finished goods 1,078,172 1,270,715 Total $ 2,118,712 $ 2,514,241

Property, Plant and Equipment25

Property, Plant and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment, Net [Abstract]
Property, Plant and Equipment	Asset Lives December 31, December 31, (in years) 2015 2014 Machinery and equipment 3 to 15 $ 15,168,377 $ 14,608,949 Building and improvements 5 to 25 3,978,387 4,360,114 Vehicles 3 to 5 90,713 90,713 Furniture, fixtures, computers and software 3 to 5 1,437,692 1,349,931 Land — 202,492 Construction in progress 682,069 568,234 Total property, plant and equipment 21,357,238 21,180,433 Less: accumulated depreciation (14,731,169) (13,561,532) Property, plant and equipment, net $ 6,626,069 $ 7,618,901

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2015
Debt [Abstract]
Summary of Debt	December 31, December 31, 2015 2014 Revolving line of credit $ 1,511,495 $ 2,071,495 Equipment line of credit $ 336,850 $ — Subordinated promissory notes $ 473,135 $ 445,452 Term notes payable: Commercial term loan $ 714,175 $ 1,009,977 Equipment term loans 879,898 640,734 Equipment notes 116,214 170,385 Total term notes payable $ 1,710,287 $ 1,821,096 Total Debt $ 4,031,767 $ 4,338,043
Future Maturities of Debt	2016 2017 2018 2019 2020 Thereafter Total Revolver $ — $ 1,511,495 $ — $ — $ — — $ 1,511,495 Subordinated promissory notes 500,000 — — — — — 500,000 Term debt and equipment notes 625,353 679,808 394,214 198,707 118,175 30,880 2,047,137 Total $ 1,125,353 $ 2,191,303 $ 394,214 $ 198,707 $ 118,175 30,880 $ 4,058,632

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Income Taxes [Abstract]
Income Tax Provision	Years Ended December 31, 2015 2014 Current: Federal $ — $ — State 932 2,168 Total current income taxes 932 2,168 Deferred: Federal — — State — — Total deferred income taxes — — Total income tax provision $ 932 $ 2,168
Deferred Income Taxes	Years Ended December 31, 2015 2014 Deferred income taxes: Current deferred tax assets: Inventories $ 93,600 $ 188,300 Bad debt reserve 23,700 65,200 Accrued expenses — 25,100 Total current deferred tax assets 117,300 278,600 Long-term deferred tax assets: Net operating loss carryforwards 3,221,000 2,982,100 Foreign net operating loss carryforwards — 291,100 Federal and state tax credit carryforwards 608,000 421,700 Patents and intangibles 68,100 73,000 Stock compensation 89,800 89,700 Other long term 45,500 142,100 Total long-term deferred tax assets 4,032,400 3,999,700 Total deferred tax assets 4,149,700 4,278,300 Current deferred tax liabilities: Prepaid expenses (64,600) (59,900) Long-term deferred tax liabilities: Property, plant and equipment (612,800) (976,400) Total deferred tax liabilities (677,400) (1,036,300) Deferred tax valuation allowance (3,472,300) (3,242,000) Net deferred tax assets (liabilities) $ — $ —
Federal Income Taxes	Years Ended December 31, 2015 2014 Tax (benefit) provision computed at statutory rate $ (145,442) $ 224,867 Increases (reductions) due to: Change in valuation allowance 230,300 (136,268) State income taxes, net of federal benefit 615 23,475 Permanent differences 479 14,561 Tax credits (federal and state) (108,194) (6,630) Utilization of deferred taxes previously reserved — (117,837) Differences on prior returns (federal and state) 23,174 — Income tax provision $ 932 $ 2,168

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2015
Shareholders' Equity [Abstract]
Fair Value of Option Grants	Years Ended December 31, 2015 2014 Expected option term 4.0 to 6.5 6.5 Expected volatility factor 23.8% to 26.7% 27% Risk-free rate .90% to 1.28% 0.96% Expected annual dividend yield —% —%
Stock Option Transactions	Weighted Weighted average Average remaining Aggregate Number of Exercise contractual Intrinsic options Price term (in years) Value Outstanding at December 31, 2014 165,800 $ 5.58 6.09 $ 305,124 Granted 62,500 6.36 Exercised (23,300) 3.44 Forfeited (19,500) 4.74 Expired (1,000) 3.67 Outstanding at December 31, 2015 184,500 6.21 6.80 $ 235,293 Exercisable at December 31, 2015 83,500 $ 6.60 4.73 $ 106,565 Exercisable at December 31, 2014 74,400 $ 6.07 4.75 $ 119,342

Earnings per share (Tables)

Earnings per share (Tables)	12 Months Ended
	Dec. 31, 2015
Earnings per Share [Abstract]
Calculation of earnings (loss) per share	Years Ended December 31, 2015 2014 Income (loss) from continuing operations $ (791,776) $ 660,988 Income (loss) from discontinued operations, net of tax 362,610 (1,779) Net income (loss) available to common shareholders $ (429,166) $ 659,209 Basic EPS: Weighted average common shares outstanding 2,784,757 2,742,080 Earnings (loss) per share - basic Continuing operations $ (0.28) $ 0.24 Discontinued operations 0.13 — Consolidated basic EPS $ (0.15) $ 0.24 Diluted EPS: Weighted average common shares outstanding 2,784,757 2,742,080 Assumed conversion of net common shares issuable under stock option plans — 91,889 Assumed conversion of net common shares issuable under warrants — 29,129 Weighted average common and common equivalent shares outstanding, diluted 2,784,757 2,863,098 Earnings (loss) per share - diluted Continuing operations $ (0.28) $ 0.23 Discontinued operations 0.13 — Consolidated diluted EPS $ (0.15) $ 0.23

Industry and Geographic Segme30

Industry and Geographic Segments (Tables)	12 Months Ended
	Dec. 31, 2015
Industry and Geographic Segments [Abstract]
Sales by Industry Segments	Revenue for the Years Ended December 31, 2015 % 2014 % Medical $ 16,770,788 78 $ 19,714,328 82 Automotive/Industrial 2,839,926 13 1,753,946 7 Military and Law Enforcement 943,603 4 1,358,568 6 Consumer Products 647,190 4 852,030 3 Other 293,677 1 391,420 2 Total $ 21,495,184 100 $ 24,070,292 100
Sales by Geographic Market	Revenue for the Years Ended December 31, 2015 % 2014 % United States $ 13,199,188 61 $ 13,050,717 54 Asia 4,774,910 22 5,168,283 21 Europe 1,662,318 9 1,344,098 6 Canada 1,607,445 7 3,791,229 16 Other 251,323 1 715,965 3 Total $ 21,495,184 100 $ 24,070,292 100

Discontinued Operations (Tables

Discontinued Operations (Tables)	12 Months Ended
	Dec. 31, 2015
Discontinued Operations [Abstract]
Assets and Liabilities of Discontinued Operations	Years Ended December 31, 2015 2014 Cash $ — $ — Total current assets from discontinued operations — — Total assets from discontinued operations $ — $ — Accounts payable and accrued expenses $ — $ 320,056 Total current liabilities from discontinued operations — 320,056 Total liabilities from discontinued operations $ — $ 320,056

Description of Business (Detail

Description of Business (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Line of Credit Facility [Line Items]
Percent of revenue derived from exports	40.00%
Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Outstanding balance, line of credit	$ 1,511,495	$ 2,071,495

Accounting Policies (Narrative)

Accounting Policies (Narrative) (Details)	12 Months Ended
	Dec. 31, 2015USD ($)customer	Dec. 31, 2014USD ($)customer
Concentration Risk [Line Items]
General revenue recognition period	3 years
Impairment of intangibles	$ 118,318	$ 63,087
Amortization expense	3,235	3,974
Estimated future amortization	1,756
Interest or penalties related to unrecognized tax positions	0
Accumulated other comprehensive income	$ 0	$ 42,502
Sales Revenue, Net [Member]
Concentration Risk [Line Items]
Number of customers, concentration of credit risk | customer	2	4
Sales Revenue, Net [Member] | Customer 1 [Member]
Concentration Risk [Line Items]
Concentration of credit risk, percentage	16.00%	15.00%
Sales Revenue, Net [Member] | Customer 2 [Member]
Concentration Risk [Line Items]
Concentration of credit risk, percentage	13.00%	13.00%
Sales Revenue, Net [Member] | Customer 3 [Member]
Concentration Risk [Line Items]
Concentration of credit risk, percentage		12.00%
Sales Revenue, Net [Member] | Customer 4 [Member]
Concentration Risk [Line Items]
Concentration of credit risk, percentage		10.00%
Accounts Receivable [Member]
Concentration Risk [Line Items]
Number of customers, concentration of credit risk | customer	5	5
Concentration of credit risk, percentage	51.00%	55.00%
Accounts Receivable [Member] | Customer 1 [Member]
Concentration Risk [Line Items]
Concentration of credit risk, percentage	9.00%	11.00%
Accounts Receivable [Member] | Two Customers [Member]
Concentration Risk [Line Items]
Number of customers, concentration of credit risk | customer	2
Accounts Receivable [Member] | Customer 2 [Member]
Concentration Risk [Line Items]
Concentration of credit risk, percentage		9.00%
Accounts Receivable [Member] | Customer 3 [Member]
Concentration Risk [Line Items]
Concentration of credit risk, percentage		15.00%
Accounts Receivable [Member] | Customer 4 [Member]
Concentration Risk [Line Items]
Concentration of credit risk, percentage		14.00%
Accounts Receivable [Member] | Four Customers [Member]
Concentration Risk [Line Items]
Number of customers, concentration of credit risk | customer		4
Patents [Member]
Concentration Risk [Line Items]
Impairment of intangibles	$ 103,287	$ 56,237
Trade Names [Member]
Concentration Risk [Line Items]
Impairment of intangibles	$ 15,031	$ 6,850

Accounting Policies (Intangible

Accounting Policies (Intangible Assets) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Gross	$ 26,626	$ 545,133
Accumulated Amortization	7,981	411,111
Net	$ 18,645	134,022
Patents and Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (in years)	10 years
Gross	$ 26,290	414,436
Accumulated Amortization	7,981	394,371
Net	18,309	20,065
Patents and Trademarks Pending [Member]
Finite-Lived Intangible Assets [Line Items]
Gross	336	97,447
Net	$ 336	97,447
Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Gross		33,250
Accumulated Amortization		16,740
Net		$ 16,510

Inventories (Details)

Inventories (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Inventories [Abstract]
Raw materials	$ 775,427	$ 873,306
Work-in-process	265,113	370,220
Finished goods	1,078,172	1,270,715
Total	2,118,712	2,514,241
Silver inventory	$ 313,738	$ 439,800

Property, Plant and Equipment36

Property, Plant and Equipment, Net (Narrative) (Details)	Dec. 04, 2015ft²item	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)
Depreciation expense | $		$ 1,461,353	$ 1,471,832
Fitchburg, Massachusetts [Member]
Number of unoccupied buildings with letter of intent to sale | item	2
Area of unoccupied buildings | ft²	52,000

Property, Plant and Equipment37

Property, Plant and Equipment, Net (Property, Plant and Equipment) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment
Machinery and equipment	$ 15,168,377	$ 14,608,949
Building and improvements	3,978,387	4,360,114
Vehicles	90,713	90,713
Furniture, fixtures, computers and software	1,437,692	1,349,931
Land		202,492
Construction in progress	682,069	568,234
Total property, plant and equipment	21,357,238	21,180,433
Less: accumulated depreciation	(14,731,169)	(13,561,532)
Property, plant and equipment, net	$ 6,626,069	$ 7,618,901
Maximum [Member] | Machinery and Equipment [Member]
Property, Plant and Equipment
Useful life	15 years
Maximum [Member] | Building and Improvements [Member]
Property, Plant and Equipment
Useful life	25 years
Maximum [Member] | Vehicles [Member]
Property, Plant and Equipment
Useful life	5 years
Maximum [Member] | Furniture, Fixtures, Computers and Software [Member]
Property, Plant and Equipment
Useful life	5 years
Minimum [Member] | Machinery and Equipment [Member]
Property, Plant and Equipment
Useful life	3 years
Minimum [Member] | Building and Improvements [Member]
Property, Plant and Equipment
Useful life	5 years
Minimum [Member] | Vehicles [Member]
Property, Plant and Equipment
Useful life	3 years
Minimum [Member] | Furniture, Fixtures, Computers and Software [Member]
Property, Plant and Equipment
Useful life	3 years

Debt (Bank Debt Narrative) (Det

Debt (Bank Debt Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Outstanding balance, line of credit	$ 1,511,495	$ 2,071,495
Percent Borrowable of net Elegible Recievable	80.00%
Percent Borrowable of net Eligible Raw Materials Inventory	50.00%
Revolver, interest rate at end of period	3.75%
Amount available under line of credit facility	$ 917,830
Revolving Credit Facility [Member] | Prime Rate [Member]
Debt Instrument [Line Items]
Spread on variable rate	0.25%
Equipment Line of Credit [Member]
Debt Instrument [Line Items]
Outstanding balance, line of credit	$ 336,850
Equipment Line Of Credit 2013 [Member] | Equipment Line of Credit [Member]
Debt Instrument [Line Items]
Outstanding balance, line of credit	$ 740,999
line of credit, interest during period	4.65%
Line of credit, draw period	1 year
line of credit, expiration period	5 years
Line of credit, maturity date	Mar. 29, 2019
Approximate monthly principal and interest payment	$ 14,000
Maximum borrowing capacity	1,000,000
Equipment Line Of Credit 2014 [Member] | Equipment Line of Credit [Member]
Debt Instrument [Line Items]
Outstanding balance, line of credit	$ 415,785
line of credit, interest during period	4.67%
Line of credit, draw period	1 year
line of credit, expiration period	5 years
Line of credit, maturity date	Jun. 26, 2020
Approximate monthly principal and interest payment	$ 8,000
Maximum borrowing capacity	1,000,000
Equipment Line Of Credit 2015 [Member] | Equipment Line of Credit [Member]
Debt Instrument [Line Items]
Outstanding balance, line of credit	$ 336,850
Line of credit, draw period	1 year
line of credit, expiration period	6 years
Line of credit, maturity date	Jun. 19, 2021
Maximum borrowing capacity	$ 1,000,000
Earliest repayment period, from date of loan	1 year
Equipment Line Of Credit 2015 [Member] | Equipment Line of Credit [Member] | Prime Rate [Member]
Debt Instrument [Line Items]
Spread on variable rate	0.25%
Term Debt And Equipment Notes [Member] | Commercial Term Loan [Member]
Debt Instrument [Line Items]
Debt, stated rate	4.25%
debt, maturity term	5 years
Approximate monthly principal and interest payment	$ 28,000

Debt (Other Debt Narrative) (De

Debt (Other Debt Narrative) (Details)	12 Months Ended
	Dec. 31, 2015USD ($)item	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)	Mar. 31, 2013USD ($)
Term Debt And Equipment Notes [Member] | Equipment Term Loans [Member]
Debt Instruments [Line Items]
Number of debt instruments | item	2
Debt instrument, face amount				$ 272,500
Approximate monthly principal and interest payment	$ 5,000
Debt instrument, term	5 years
Debt, stated rate	4.66%
Subordinated Promissory Notes [Member]
Debt Instruments [Line Items]
Debt instrument, face amount			$ 500,000
Interest rate	12.00%	10.00%	10.00%
Debt, fair value	$ 416,950
Fair value of warrants subordinated debt	83,050
Non-cash interest expense	27,683	$ 27,683
Unamortized discount	$ 26,865

Debt (Summary of Debt) (Details

Debt (Summary of Debt) (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Subordinated promissory notes	$ 473,135	$ 445,452
Total Debt	4,031,767	4,338,043
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Revolving line of credit	1,511,495	2,071,495
Equipment Line of Credit [Member]
Debt Instrument [Line Items]
Revolving line of credit	336,850
Term Debt And Equipment Notes [Member]
Debt Instrument [Line Items]
Term notes payable	1,710,287	1,821,096
Term Debt And Equipment Notes [Member] | Commercial Term Loan [Member]
Debt Instrument [Line Items]
Term notes payable	714,175	1,009,977
Term Debt And Equipment Notes [Member] | Equipment Term Loans [Member]
Debt Instrument [Line Items]
Term notes payable	879,898	640,734
Term Debt And Equipment Notes [Member] | Equipment Notes [Member]
Debt Instrument [Line Items]
Term notes payable	$ 116,214	$ 170,385

Debt (Future Minimum of Debt) (

Debt (Future Minimum of Debt) (Details)	Dec. 31, 2015USD ($)
Future maturities of debt
2,016	$ 1,125,353
2,017	2,191,303
2,018	394,214
2,019	198,707
2,020	118,175
Thereafter	30,880
Long-term Debt, Total	4,058,632
Revolving Credit Facility [Member]
Future maturities of debt
2,016	0
2,017	1,511,495
2,018	0
2,019	0
2,020	0
Thereafter	0
Long-term Debt, Total	1,511,495
Subordinated Promissory Notes [Member]
Future maturities of debt
2,016	500,000
2,017	0
2,018	0
2,019	0
2,020	0
Thereafter	0
Long-term Debt, Total	500,000
Term Debt And Equipment Notes [Member]
Future maturities of debt
2,016	625,353
2,017	679,808
2,018	394,214
2,019	198,707
2,020	118,175
Thereafter	30,880
Long-term Debt, Total	$ 2,047,137

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details)	12 Months Ended
	Dec. 31, 2015USD ($)
Operating Loss Carryforwards [Line Items]
Federal statutory income tax rate	34.00%
Federal Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 8,195,636
Tax Credit Carryforward, Amount	361,000
State Jurisdiction [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	8,231,513
Tax Credit Carryforward, Amount	$ 380,000

Income Taxes (Income Tax Provis

Income Taxes (Income Tax Provision) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Current:
State	$ 932	$ 2,168
Total current income taxes	932	2,168
Income tax provision	$ 932	$ 2,168

Income Taxes (Deferred Income T

Income Taxes (Deferred Income Taxes) (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Current deferred tax assets:
Inventories	$ 93,600	$ 188,300
Bad debt reserve	23,700	65,200
Accrued expenses	0	25,100
Total current deferred tax assets	117,300	278,600
Long-term deferred tax assets:
Net operating loss carryforwards	3,221,000	2,982,100
Foreign net operating loss carryforwards	0	291,100
Federal and state tax credit carryforward	608,000	421,700
Patents and intangibles	68,100	73,000
Stock compensation	89,800	89,700
Other long term	45,500	142,100
Total long-term deferred tax assets	4,032,400	3,999,700
Total deferred tax assets	4,149,700	4,278,300
Current deferred tax liabilities:
Prepaid expenses	(64,600)	(59,900)
Long-term deferred tax liabilities:
Property, plant and equipment	(612,800)	(976,400)
Total deferred tax liabilities	(677,400)	(1,036,300)
Deferred tax valuation allowance	(3,472,300)	(3,242,000)
Net deferred tax assets (liabilities)	$ 0	$ 0

Income Taxes (Federal Income Ta

Income Taxes (Federal Income Taxes) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income Taxes [Abstract]
Tax (benefit) provision computed at statutory rate	$ (145,442)	$ 224,867
Change in valuation allowance	230,300	(136,268)
State income taxes, net of federal benefit	615	23,475
Permanent differences	479	14,561
Tax credits (federal and state)	(108,194)	(6,630)
Utilization of deferred taxes previously recorded		(117,837)
Differences on prior returns (federal and state)	23,174
Income tax provision	$ 932	$ 2,168

Employee Benefit Plans (Details

Employee Benefit Plans (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Employee Benefit Plans [Abstract]
Maximum annual contribution per employee, percent of eligible compensation	90.00%
Matching 401K contribution	$ 47,858	$ 46,958

Commitments and Contingencies -

Commitments and Contingencies - (Details)	12 Months Ended
	Dec. 31, 2014agreement	Dec. 31, 2015USD ($)
Commitments and Contingencies [Abstract]
Number of operating lease agreements | agreement	2
Operating lease payments due in 2016		$ 7,287
Operating lease payments due in 2017		$ 1,602

Shareholders' Equity (Narrative

Shareholders' Equity (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividends declared or paid	$ 0	$ 0
Subordinated debt, warrants of common stock issued			100,000
Warrants exercisable commencing period	6 months
Warrants exercisable period	3 years
Exercise price of warrants	$ 3.51
Proceeds from warrant exercises	$ 0	$ 105,300
Warrants exercised	0	30,000
Warrants unexercised	70,000	70,000
Shares outstanding	2,801,639	2,778,339
Number of options, Granted in period	62,500	7,500
Intrinsic value of options exercised	$ 60,197	$ 80,800
Exercised in period	23,300
Share-based compensation expense	$ 29,178	33,390
Unrecognized compensation costs related to non-vested shares	$ 134,160	$ 86,896
Unrecognized compensation costs, recognized over weighted average period	3 years 2 months 12 days
Weighted average grant date fair value	$ 1.66
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, New Issues		26,100
2001 and 2010 Plans [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares outstanding	184,500
The 2001 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares outstanding	15,000
The 2010 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized for issuance	500,000
Vesting period	5 years
Shares outstanding	169,500
Shares available for future grants	318,000
The 2010 Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Contractual Term	10 years
The 2010 Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Contractual Term	6 years
Treasury stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of common stock from treasury, shares	23,300	26,100

Shareholders' Equity (Fair Valu

Shareholders' Equity (Fair Value of Option Grants) (Details)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Fair Value, Option, Quantitative Disclosures [Line Items]
Expected option term, years		6 years 6 months
Expected volatility factor		27.00%
Risk-free rate		0.96%
Minimum [Member]
Fair Value, Option, Quantitative Disclosures [Line Items]
Expected option term, years	4 years
Expected volatility factor	23.80%
Risk-free rate	0.90%
Maximum [Member]
Fair Value, Option, Quantitative Disclosures [Line Items]
Expected option term, years	6 years 6 months
Expected volatility factor	26.70%
Risk-free rate	1.28%

Shareholders' Equity (Stock Opt

Shareholders' Equity (Stock Option Transactions) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Shareholders' Equity [Abstract]
Number of options, Outstanding, Beginning Balance	165,800
Weighted Average Exercise Price, Outstanding	$ 5.58
Weighted average remaining contractual term (in years), Outstanding	6 years 9 months 18 days	6 years 1 month 2 days
Aggregate Intrinsic Value, Outstanding	$ 305,124
Number of options, Granted in period	62,500	7,500
Weighted Average Exercise Price, Granted in period	$ 6.36
Number of options, Exercised in period	(23,300)
Weighted Average Exercise Price, Exercised in period	$ 3.44
Number of options, Forfeited in period	(19,500)
Weighed Average Exercise Price, Forfeited in period	$ 4.74
Number of options, Expired in period	(1,000)
Weighted Average Exercise Price, Expired in period	$ 3.67
Number of options, Outstanding, Ending Balance	184,500	165,800
Weighted Average Exercise Price, Outstanding	$ 6.21	$ 5.58
Aggregate Intrinsic Value, Outstanding	$ 235,293	$ 305,124
Number of options, Exercisable	83,500	74,400
Weighted Average Exercise Price, Exercisable	$ 6.60	$ 6.07
Weighted average remaining contractual term (in years), Exercisable	4 years 8 months 23 days	4 years 9 months
Aggregate Intrinsic Value, Exercisable	$ 106,565	$ 119,342

Earnings per share (Narrative)

Earnings per share (Narrative) (Details) - shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Options outstanding	184,500	165,800
Warrants to purchase outstanding	70,000	70,000
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares	184,500	47,500
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares	0

Earnings per share (Calculation

Earnings per share (Calculation of earnings (loss) per share ) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Earnings per Share [Abstract]
Income (loss) from continuing operations	$ (791,776)	$ 660,988
Income (loss) from discontinued operations, net of tax	362,610	(1,779)
Net income (loss)	$ (429,166)	$ 659,209
Basic EPS:
Weighted average common shares outstanding	2,784,757	2,742,080
Earnings (loss) per share - basic
Continuing operations	$ (0.28)	$ 0.24
Discontinued operations	0.13	0
Earnings (loss) per share - basic	$ (0.15)	$ 0.24
Diluted EPS:
Assumed conversion of net common shares issuable under stock option plans	0	91,889
Assumed conversion of net common shares issuable under warrants	0	29,129
Weighted average common and common equivalent shares outstanding, diluted	2,784,757	2,863,098
Earnings (loss) per share - diluted
Continuing operations	$ (0.28)	$ 0.23
Discontinued operations	0.13	0
Earnings (loss) per share - diluted	$ (0.15)	$ 0.23

Industry and Geographic Segme53

Industry and Geographic Segments (Sales by Industry Segments) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Segment Reporting Information [Line Items]
Revenues	$ 21,495,184	$ 24,070,292
Revenue by Percent	100.00%	100.00%
Medical [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues	$ 16,770,788	$ 19,714,328
Revenue by Percent	78.00%	82.00%
Automotive/Industrial [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues	$ 2,839,926	$ 1,753,946
Revenue by Percent	13.00%	7.00%
Military and Law Enforcement [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues	$ 943,603	$ 1,358,568
Revenue by Percent	4.00%	6.00%
Consumer Products [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues	$ 647,190	$ 852,030
Revenue by Percent	4.00%	3.00%
Other Product/Service [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues	$ 293,677	$ 391,420
Revenue by Percent	1.00%	2.00%

Industry and Geographic Segme54

Industry and Geographic Segments (Sales by Geographic Market) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 21,495,184	$ 24,070,292
Revenue by Percent	100.00%	100.00%
United States [Member] | Operating Segments [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 13,199,188	$ 13,050,717
Revenue by Percent	61.00%	54.00%
Asia [Member] | Operating Segments [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 4,774,910	$ 5,168,283
Revenue by Percent	22.00%	21.00%
Europe [Member] | Operating Segments [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 1,662,318	$ 1,344,098
Revenue by Percent	9.00%	6.00%
Canada [Member] | Operating Segments [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 1,607,445	$ 3,791,229
Revenue by Percent	7.00%	16.00%
Other Geographic Markets [Member] | Operating Segments [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 251,323	$ 715,965
Revenue by Percent	1.00%	3.00%

Discontinued Operations (Narrat

Discontinued Operations (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Accumulated other comprehensive income	$ 0	$ 42,502
Discontinued Operations [Member] | WirelessDx [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue from discontinued operations	362,610
Liabilities write-off of discontinued operations	320,056
Discontinued Operations [Member] | WirelessDx [Member] | Scenario, Adjustment [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Accumulated other comprehensive income	$ (42,553)

Discontinued Operations (Assets

Discontinued Operations (Assets and Liabilities of the Discontinued Operations) (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash	$ 0	$ 0
Total current liabilities from discontinued operations	0	320,056
Discontinued Operations [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash	0	0
Total current assets from discontinued operations	0	0
Total assets from discontinued operations	0	0
Accounts payable and accrued expenses	0	320,056
Total current liabilities from discontinued operations	0	320,056
Total Liabilities from discontinued operations	$ 0	$ 320,056

Subsequent Events - (Details)

Subsequent Events - (Details)	Jan. 31, 2016item
Fitchburg, Massachusetts [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Number of unoccupied buildings with entered into agreement to sale	2